<DOC>
	<DOCNO>NCT00055640</DOCNO>
	<brief_summary>RATIONALE : Analyzing gene present cancer cell may useful method predict response non-Hodgkin 's lymphoma cancer treatment . Imaging procedure positron emission tomography ( PET ) scan may improve ability measure well cancer respond treatment . PURPOSE : This phase II trial study molecular risk assessment see well work predict response therapy patient receive treatment non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Molecular Risk Assessment Planning Treatment Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether molecular risk assessment identify group patient diffuse large B-cell non-Hodgkin 's lymphoma ( NHL ) demonstrate least 50 % difference early response rate treatment determine positron-emission tomography ( PET ) imaging . - Determine , PET image , response rate patient treat cyclophosphamide , doxorubicin , vincristine , prednisone , rituximab . - Determine whether early response rate predict gene expression profile diagnosis patient . - Compare gene expression profile patient refractory relapse large cell NHL profile disease diagnosis . - Determine relapse-free overall survival rate patient . - Determine feasibility new NHL treatment algorithm base prognostic index molecular risk , early response assessment PET imaging . OUTLINE : Molecular risk assessment perform use lymph node tissue initial diagnosis test `` activate '' gene start treatment . Patients receive rituximab IV 3-6 hour , cyclophosphamide IV 30 minute , doxorubicin IV 5 minute , vincristine IV 5 minute day 1 oral prednisone day 1-5 . Treatment repeat every 21 day 3-8 course . Patients undergo whole-body positron-emission tomography ( PET ) scan baseline course 3 determine response . Results genetic test PET scan use determine treatment recommendation . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 36-50 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diffuse large Bcell nonHodgkin 's lymphoma CD20 and/or CD19 positive immunohistochemistry flow cytometry Disease evaluable positronemission tomography scan Diagnostic tissue ( either freeze fresh unfixed ) available molecular test willing undergo repeat procedure obtain tissue No CNS involvement lymphoma PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin great 3 mg/dL Renal Creatinine great 3 mg/dL Cardiovascular LVEF least 40 % Other Not pregnant nursing Fertile patient must use effective contraception No significant organ dysfunction would preclude study chemotherapy HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy No prior biological response modifier therapy Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy No prior radioimmunotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>